Equity Overview
Price & Market Data
Price: $10.09
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $185,616,384
Daily Volume: 0
Performance Metrics
1 Week: 0.10%
1 Month: -13.24%
3 Months: 28.37%
6 Months: -8.61%
1 Year: 89.84%
YTD: 26.76%
Company Details
Employees: 33
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.